This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ2C0EU_L.jpg
The deal, Pfizer’s largest since its $67 billion acquisition of Wyeth in 2009, will add four approved cancer therapies with combined sales of nearly $2 billion in 2022.
Analysts expect that sales to double by 2025, according to Refinitiv data.
Pfizer has offered $229 in cash per Seagen share, a 32.7% premium to Friday’s closing price.
Shares of Seagen were up 23% before the bell.
